1. Introduction {#sec1-cancers-11-00754}
===============

Extramammary Paget disease (EMPD) is an uncommon cutaneous adenocarcinoma most often arising in older patients (approximately 95% of patients were \>50 years old) and in the anogenital area (approximately 90% of cases) or axilla (approximately 7% of cases) \[[@B1-cancers-11-00754],[@B2-cancers-11-00754],[@B3-cancers-11-00754],[@B4-cancers-11-00754]\]. The tumor cells are most often confined to the epithelium ([Figure 1](#cancers-11-00754-f001){ref-type="fig"}A) but occasionally invade the underlying dermis or submucosa. Currently, treatment of EMPD generally includes aggressive surgical extirpation, but this can be associated with high patient morbidity \[[@B5-cancers-11-00754],[@B6-cancers-11-00754]\]. Even with aggressive surgical excision, EMPD exhibits a high rate of local recurrence (44 of 174 cases (25%) in a Mayo Clinic study \[[@B7-cancers-11-00754]\]) owing to multifocality and subclinical extension; rarely, nodal and systemic metastases develop (10 of 261 cases (3.8%) in the Mayo Clinic study \[[@B7-cancers-11-00754]\]). Effective systemic therapies for metastatic or locally advanced disease are lacking.

Immune checkpoint inhibitors have recently been approved by the US Food and Drug Administration (FDA) for treatment of non-small cell lung cancer, melanoma, and other types of cancers \[[@B8-cancers-11-00754],[@B9-cancers-11-00754],[@B10-cancers-11-00754],[@B11-cancers-11-00754],[@B12-cancers-11-00754]\]. Many immune checkpoint inhibitors target programmed cell death receptor (PD-1) and its ligand (PD-L1) interaction. Interaction between the PD-1 receptor on cytotoxic T cells and its ligands PD-L1 and PD-L2 on tumor cells is a mechanism by which neoplastic cells can dampen the tumor-specific immune response and evade anti-tumor immunity \[[@B13-cancers-11-00754]\]. Immune cells in the tumor microenvironment, including T lymphocytes \[[@B14-cancers-11-00754],[@B15-cancers-11-00754]\] and macrophages \[[@B16-cancers-11-00754],[@B17-cancers-11-00754]\], are also known to express PD-L1, interact with PD-1 on cytotoxic T cells, and contribute to tumor immune escape. Thus, blocking immune checkpoints can enhance the anti-tumor responses by activation of the tumor-associated immune infiltrate and propagation of the anti-tumor immune response. Our previous study showed a direct relationship between the density of the tumor-associated immune infiltrate and/or tumor cell expression of PD-L1 with clinical response to immune checkpoint blockade \[[@B18-cancers-11-00754]\].

Given the advances of immunotherapy in other tumors and the paucity of effective agents to treat locally advanced or metastatic EMPD, we sought to quantify the density and composition of the tumor-associated immune infiltrate in EMPD and further to determine PD-L1 expression in EMPD tumor cells.

2. Results {#sec2-cancers-11-00754}
==========

2.1. Patient Demographic and Clinical-Pathologic Characteristics {#sec2dot1-cancers-11-00754}
----------------------------------------------------------------

Demographic and clinical-pathologic characteristics for the 21 patients with EMPD are summarized in [Table 1](#cancers-11-00754-t001){ref-type="table"} and [Table 2](#cancers-11-00754-t002){ref-type="table"}. Our cohort consisted of 11 men and 10 women with a mean age of 68 years (range, 48--79 years). Twenty specimens were from available primary tumors, and one was from a metastatic lymph node since the primary tumor tissue was not available for further study. Ten patients had a history of other cancers, and seven of these patients had another non-skin cancer involving the prostate in two patients, breast in two, colon--rectum in one, kidney (clear cell carcinoma) in one, and lung in one. The median follow-up period for all EMPD patients was 59.2 months (range, 2.8--185.0 months).

2.2. EMPD Treatment and Outcomes {#sec2dot2-cancers-11-00754}
--------------------------------

All patients were initially treated with wide local excision, after which 17 patients (81%) had positive margins. Of the 17 patients with positive margins, nine underwent re-excision, and eight of these nine continued to have positive margins despite multiple attempts at surgical extirpation. One patient received laser ablation and fulguration for residual disease, and one patient received topical imiquimod treatment for recurrent disease.

Seven (33%) of the 21 patients experienced local recurrence, and one patient had persistent disease despite treatment. Three patients (14%) with metastatic disease received docetaxel and carboplatin. One of the three patients also received intensity-modulated radiation therapy to a total dose of 66 Gy in 33 fractions to the primary tumor site and bilateral inguinal lymph nodes. One patient underwent bilateral superficial and deep inguinal lymph node dissection and salvage systemic therapy with gemcitabine, 5-fluorouracil, cisplatin, and leucovorin for a total of seven cycles for recurrent tumor after initial chemotherapy. All three patients with nodal and systemic metastasis died of disease. None of the five patients with negative final margins after wide local excision experienced local recurrence or metastasis.

One patient (patient 17 in [Table 2](#cancers-11-00754-t002){ref-type="table"}) had a tumor broadly involving the anogenital area with extension to vulva, vagina, and ectocervix diagnosed on subsequent hysterectomy. Seven patients had an associated invasive component. One of these seven patients (patient 20 in [Table 2](#cancers-11-00754-t002){ref-type="table"}) had a concurrent rectal adenocarcinoma, and the EMPD in this patient likely represented secondary EMPD (CK7+, CK20+, CDX2−). One patient (patient 17 in [Table 2](#cancers-11-00754-t002){ref-type="table"}) had invasive adenocarcinoma involving the urinary bladder diagnosed 11 years after an initial diagnosis of extensive anogenital EMPD; this bladder adenocarcinoma was likely related to the EMPD, as suggested by its immunophenotype (CK7+, CK20−, GCDFP15+).

Of the seven patients with invasive EMPD, three (patients 15, 18, and 21 in [Table 2](#cancers-11-00754-t002){ref-type="table"}) had the depth of invasion reported, as focal invasion, \<0.5 mm and 10 mm, respectively. The patient with 10 mm invasion developed systemic metastasis, which was treated with chemotherapy, and died of disease. The patient with \<0.5 mm invasion did not have nodal or systemic metastasis. She was treated with multiple local excisions, laser therapy, and imiquimod and was alive with multiple recurrences 14 years after initial diagnosis of EMPD and 13 years after diagnosis of invasive disease. The patient with focal invasion had wide local excision for EMPD with positive margins and was lost to follow-up.

2.3. Expression of PD-L1 in EMPD and MPD {#sec2dot3-cancers-11-00754}
----------------------------------------

A representative example of EMPD and the density and composition of the tumor-associated immune infiltrate is shown in [Figure 1](#cancers-11-00754-f001){ref-type="fig"}. Results of analysis of immunohistochemical (IHC) staining in the EMPD cases are summarized in [Table 2](#cancers-11-00754-t002){ref-type="table"}. The expression of PD-L1 in tumor cells was detected in three of 21 (14%) EMPD cases but none of the MPD cases. In contrast, PD-L1 expression in the tumor-associated lymphocytic infiltrate was detected in 15 of 21 (71%) EMPD cases and all 10 (100%) MPD cases. Among the patients with mammary Paget disease (MPD), PD-L1 expression in lymphocytes was lower in patients with HER2/neu-positive disease (median H-score, 2.0; range, 1.0--6.0) than in patients with HER2/neu-negative disease (median H-score, 40.0; range, 6.0--60.0; *p* = 0.07). In the EMPD cases, none of the clinical-pathologic parameters assessed (including overall survival, disease-specific survival, and time to metastasis) or the relative density of CD3+, CD8+, or PD-1+ cells in tumor-associated lymphocytes quantified by automated image analysis (positive cells/mm^2^) significantly correlated with PD-L1 positivity (H-score) in tumor cells ([Supplementary Materials](#app1-cancers-11-00754){ref-type="app"} [Table S1](#app1-cancers-11-00754){ref-type="app"}).

2.4. Correlation of Density and Composition of Tumor-Associated Immune Infiltrates with Clinical-Pathologic Parameters {#sec2dot4-cancers-11-00754}
----------------------------------------------------------------------------------------------------------------------

Immunohistochemical studies for CD3, CD8, and PD-1 were performed, and the relative densities of IHC+ cells associated with the tumor ([Figure 1](#cancers-11-00754-f001){ref-type="fig"}) were quantified using automated image analysis. Patients who were still alive at last follow-up had significantly higher CD3+ values (median, 1310 cells/mm^2^; range, 543--2115) compared with those who died (median, 611 cells/mm^2^; range, 481--908; *p* = 0.049). None of the other clinical-pathologic parameters assessed (including overall survival, disease-specific survival, and time to metastasis) significantly correlated with PD-L1 positivity (H-score) in tumor cells or with the relative density of CD3+, CD8+ or PD-1+ cells in tumor-associated lymphocytes ([Table 2](#cancers-11-00754-t002){ref-type="table"} and [Supplementary Materials](#app1-cancers-11-00754){ref-type="app"} [Tables S1--S4](#app1-cancers-11-00754){ref-type="app"}).

3. Discussion {#sec3-cancers-11-00754}
=============

In our study, PD-L1 was expressed in tumors in three of 21 EMPD cases and in the tumor-associated immune infiltrate in 15 of the 18 EMPD cases evaluated by automated image analysis. A prior study in metastatic bladder carcinoma showed that tumors with PD-L1-positive tumor-infiltrating immune infiltrates had higher response rates to anti--PD-L1 therapy \[[@B19-cancers-11-00754]\]. Thus, our findings suggest that immune checkpoint blockade might be a feasible approach for locally advanced or metastatic EMPD.

The upregulation of PD-L1 in tumor cells has been identified in basal, ERBB2-enriched, and inflammatory breast cancers \[[@B20-cancers-11-00754],[@B21-cancers-11-00754],[@B22-cancers-11-00754]\]. The upregulation PD-L1 also correlated with better response to neoadjuvant chemotherapy in basal and ERBB2-enriched breast cancers \[[@B20-cancers-11-00754]\]. Currently, several clinical trials are evaluating the effectiveness of checkpoint inhibitors targeting PD-1/PD-L1 in breast cancer \[[@B23-cancers-11-00754]\]. In this study, we found lower PD-L1 expression in lymphocytes of MPD patients with HER2/neu expression. However, additional studies with larger sample sizes are necessary to further evaluate these preliminary data.

In a previous study \[[@B24-cancers-11-00754]\], PD-L1 was not expressed by any neoplastic cells of EMPD or MPD or the associated lymphocytes. In contrast, in our study, tumor cells did not express PD-L1 in any of the MPD cases, but tumor cells expressed PD-L1 in 14% of the EMPD cases. In addition, PD-L1 in the tumor-associated lymphocytic infiltrate was detected in 71% of the EMPD cases and all of the MPD cases. The discrepancy in findings between our study and the previous study might be due to the differences in dilutions or methods of using PD-L1 antibody despite the same clone (22C3) and similar cut-off values for interpretation. In that previous study, PD-L1 (Dako Agilent, clone 22C3, 1:50) was used with a cut-off value of 1% for positive PD-L1 expression. In our study, a commercially available FDA-approved PD-L1 antibody (pre-made kit) was used, and we followed the manufacturer's recommendation for processing and interpretation \[[@B25-cancers-11-00754]\]; the cut-off value for positive PD-L1 expression was 1%.

As expected with IHC assays, PD-L1 interpretation is not without challenges. Review of the literature shows different cut-off values for PD-L1 positivity, and different studies use different methods of PD-L1 scoring, basing it on tumor cells only, immune infiltrate only, or both \[[@B26-cancers-11-00754],[@B27-cancers-11-00754],[@B28-cancers-11-00754],[@B29-cancers-11-00754],[@B30-cancers-11-00754],[@B31-cancers-11-00754]\]. There is poor interobserver agreement among pathologists in scoring PD-L1 in the tumor-associated immune infiltrate, and although patients with higher PD-L1 tumor proportion score might show clear benefit with immune checkpoint inhibitor treatment, subsets of patients with negative or lower levels of PD-L1 may also respond \[[@B32-cancers-11-00754]\]. Hence, the FDA is currently not using cut-off values for PD-L1 by IHC in many tumors for which checkpoint inhibitors are approved. Although our study has certain limitations and only 14% of EMPD cases in our study had tumor cells positive for PD-L1, clinical trials of immune checkpoint inhibitors in EMPD might prove beneficial, especially in patients with metastatic EMPD. However, a larger study using similar analysis is necessary to confirm our findings.

In addition, our study showed that none of the clinical-pathologic parameters assessed (including overall survival, disease-specific survival, and time to metastasis) significantly correlated with the relative density of CD3+ cells in tumor-associated lymphocytes, with the exception that EMPD patients who were still alive had significantly higher CD3+ T cell densities than patients who died. Similarly, in the previous study mentioned above \[[@B24-cancers-11-00754]\], the density of CD3+ T cells did not correlate with any of the clinical factors studied, including age, sex, localization, or recurrence.

Moreover, our study shows that among the patients with MPD, PD-L1 expression in lymphocytes was lower in patients with HER2/neu-positive disease than in patients with HER2/neu-negative disease. However, the lack of available survival data and status of HER2/neu in MPD patients in the previous study \[[@B24-cancers-11-00754]\] precludes a direct comparison of the findings and underscores the need for additional study with a larger sample size and complete clinical outcome data.

There is a paucity of clinical studies examining therapeutic options for EMPD, and thus there is no widely accepted standard of care. The primary modality of treatment for EMPD is wide local excision or Mohs micrographic surgery \[[@B5-cancers-11-00754],[@B6-cancers-11-00754]\]. Extramammary Paget disease is associated with a high rate of local recurrence after surgery \[[@B7-cancers-11-00754]\], which is attributed to the difficulty of determining margin status due to the EMPD's multifocal pattern of growth, tendency to arise as an ill-defined non-mass lesion, and frequent extensive subclinical extension. Non-surgical treatment options for EMPD include topical imiquimod \[[@B33-cancers-11-00754]\], photodynamic therapy, radiation therapy, carbon dioxide therapy, anti-androgen therapy, targeted anti-HER2/neu therapy (trastuzumab) \[[@B34-cancers-11-00754],[@B35-cancers-11-00754]\], and cytotoxic chemotherapy \[[@B7-cancers-11-00754],[@B36-cancers-11-00754]\]. Currently, there is no widely accepted treatment regimen for metastatic EMPD, and case studies and reports have shown that the systemic chemotherapy-based regimens used in the past had limited success. Hence, it is necessary to explore the possible utility of immunotherapy for EMPD, at least for metastatic EMPD \[[@B37-cancers-11-00754]\].

4. Materials and Methods {#sec4-cancers-11-00754}
========================

4.1. Case Selection and Diagnosis {#sec4dot1-cancers-11-00754}
---------------------------------

With approval from the Institutional Review Board of the University of Texas MD Anderson Cancer Center (protocol no. PA16-0424), we identified and reviewed 21 cases of EMPD from 21 patients who were treated and followed at our institution from 2005 through 2016. Some of these cases may have been included in a previously published study \[[@B38-cancers-11-00754]\]. Ten additional cases of MPD from 10 patients treated and followed at our institution from 2005 through 2016 were identified and reviewed. Patient records were reviewed to obtain demographic parameters (i.e., sex and age) and clinical-pathologic parameters (i.e., tumor anatomic site, final margin status of excision, associated invasive carcinoma, metastasis, local recurrence, history of other cancers, and vital status at last follow-up).

4.2. Immunohistochemistry {#sec4dot2-cancers-11-00754}
-------------------------

The protein expression of PD-L1 was assessed by immunohistochemistry using a commercial FDA-approved companion diagnostic assay (pre-made kit for PD-L1) in a CLIA-certified laboratory using the anti--PD-L1 antibody clone 22C3 (Dako, Carpentaria, CA), a mouse anti-human PD-L1 immunoglobulin G1-kappa generated through murine immunization with a fusion protein containing the human extracellular domain of PD-L1 \[[@B25-cancers-11-00754]\]. In addition, IHC studies were performed using antibodies for CD3 (Dako A0452; 1:100), CD8 (LifeSciences Technology MS457s; 1:25), and PD-1 (Abcam ab137132; 1:250) on an automated Leica Bond immunostainer (Leica Biosystems, Buffalo Grove, IL, USA) and 3,30-diaminobenzidine chromogen per the manufacturer's recommendations. We performed a positive control and a negative control in every run of the immunohistochemical study according to the manufacturers' guidelines.

4.3. Visual Analysis of IHC Staining {#sec4dot3-cancers-11-00754}
------------------------------------

The PD-L1 IHC staining was evaluated independently by 2 pathologists (P.P.A. and S.H.M.). The intensity of staining was assessed on a scale of 0 to 3 (0 = negative; 1 = mild; 2 = moderate; 3 = strong), while the extent of staining was assessed as a percentage of positive tumor cells or immune cells in increments of 10 percentage points. The positive expression of PD-1 and PD-L1 were defined as staining in ≥1% (partial or complete membranous pattern) of tumor cells in agreement with FDA-approved criteria \[[@B39-cancers-11-00754]\]. A score incorporating both intensity and positivity ("H-score") was calculated by multiplying staining intensity by percentage of positive tumor cells. Discrepant cases were reviewed to obtain a consensus. Immune cells showing membranous (partial or complete) staining for CD3 and CD8 were evaluated independently by the 2 pathologists in a similar fashion to obtain an H-score. Extramammary Paget disease cases were evaluated for CD3, CD8, PD-1, and PD-L1 in immune infiltrate and PD-1 and PD-L1 in tumor cells by visual analysis. The MPD cases were evaluated for PD-L1 in immune infiltrate and tumor cells by visual analysis.

To facilitate interpretation of the IHC staining and to better ascertain the presence and/or localization of tumor cells, cytokeratin 7 immunostaining was used in the majority of samples to localize the neoplastic cells.

4.4. Automated Image Analysis of Immune Infiltrate and PD-1 {#sec4dot4-cancers-11-00754}
-----------------------------------------------------------

Eighteen (86%) of the 21 cases of EMPD were subjected to evaluation of CD3, CD8, and PD-1 in the immune infiltrate by automated image analysis. Three cases were excluded from automated image analysis because of metastatic disease in a lymph node (*n* = 1), a scant immune infiltrate (*n* = 1), or a small biopsy specimen (*n* = 1). The slides chosen were scanned at 20× magnification (Aperio ScanScope AT Turbo; Leica Biosystems). With the help of image analysis software (Aperio ImageScope), three 1 mm^2^ squares were designated in the areas of highest density of immune cells positive for the IHC marker in question. The number of cells positive for the marker in each of the 3 squares was then counted using a modified nuclear algorithm, as described in our previous study \[[@B18-cancers-11-00754]\]. For each tumor, the mean number of cells positive per square was then calculated to obtain a final number of positive cells per mm^2^ for each case.

4.5. Statistical Methods {#sec4dot5-cancers-11-00754}
------------------------

Demographic and clinical-pathologic parameters were summarized for all patients and for subgroups of patients defined by PD-L1 expression in tumor cells and the tumor-associated lymphocytic infiltrate. Categorical variables were summarized by frequencies and percentages and assessed using either Fisher's exact test or generalized Fisher's exact test; continuous measures were summarized by mean, standard deviation, median, and range (minimum, maximum) and assessed using either Wilcoxon rank--sum exact test or Kruskal--Wallis exact test. Correlations between continuous measures were determined using Spearman correlation coefficient.

Overall survival and disease-specific survival were computed from the date of sample collection to the last known follow-up date. Patients alive at the last follow-up date were censored for overall survival, and patients who died of causes other than EMPD and those who were alive at the last follow-up date were censored for disease-specific survival. Time to metastasis was computed from the date of sample collection to the date of metastasis. Patients who did not experience metastasis were censored at the last follow-up date. Overall survival, disease-specific survival, and time to metastasis were estimated using the Kaplan--Meier method, and the log--rank test was used to assess differences between groups.

All statistical analyses were performed using SAS 9.3 for Windows (SAS Institute Inc., Cary, NC, USA). All statistical tests used a significance level of 5%. No adjustments for multiple testing were made.

5. Conclusions {#sec5-cancers-11-00754}
==============

In our series, three of 21 patients with EMPD had PD-L1+ tumor cells, and the associated immune infiltrate consisted of varying densities of CD3+, CD8+, PD-1+, and PD-L1+ cells. With the exception of vital status and CD3+, there was no significant association between these findings and clinical-pathologic parameters, including overall survival and time to metastasis.

We thank Stephanie Deming, a Senior Scientific Editor in the Department of Scientific Publications, for help with editing this paper.

The following are available online at <https://www.mdpi.com/2072-6694/11/6/754/s1>, Table S1: Correlation of PD-L1 expression with density and composition of tumor-associated immune infiltrates and clinical-pathologic parameters in EMPD, Table S2: Correlation of density of CD3+ tumor-associated immune infiltrate and clinical-pathologic parameters in EMPD, Table S3: Correlation of density of CD8+ tumor-associated immune infiltrate and clinical-pathologic parameters in EMPD, Table S4. Correlation of density of PD-1+ tumor-associated immune infiltrate and clinical-pathologic parameters in EMPD, Figure S1. 1A--D: Representative sections of PD-L1 control. PD-L1 22C3-positive control of cell line NCL-H226 (A: low power and B: high power) and negative control: Cell line MCF-7 (C: low power and D: high power).
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![Immune infiltrate associated with extramammary Paget disease (EMPD). (**A**--**E**) Representative hematoxylin-eosin-stained sections showing (**A**) intraepithelial tumor component (100×) (inset, cytokeratin-7 immunohistochemical (IHC) study highlighting EMPD tumor cells; 100×) and (**B**) CD3+ lymphocytes (100×), (**C**) CD8+ lymphocytes (100×), (**D**) PD-1+ lymphocytes (100×), and (**E**) PD-L1+ lymphocytes (100×) in the tumor-associated immune infiltrate. (**F**) Weak and predominantly partial membranous expression of PD-L1 in EMPD tumor cells (200×), shown for comparison (1--2+ intensity).](cancers-11-00754-g001){#cancers-11-00754-f001}

cancers-11-00754-t001_Table 1

###### 

Summary of demographic and clinical-pathologic findings in patients with extramammary Paget disease (EMPD) and mammary Paget disease (MPD).

  EMPD (*n* = 21)                       MPD (*n* = 10)                                           
  ------------------------------------- ---------------- --------------------------------------- ------------
  Age, years                                             Age, years                              
  Mean                                  67.7             Mean                                    50.5
  Median                                67.8             Median                                  51.9
  Min, max                              48.0, 79.0       Min, max                                22.9, 70.6
  Sex, *n*                                               Tumor type in ipsilateral breast, *n*   
  Male                                  11               IDC                                     6
  Female                                10               ILC                                     1
  Anatomic site, *n*                                     DCIS only                               1
  Perianal region                       5                LCIS only                               0
  Vulva                                 6                DCIS + LCIS                             1
  Scrotum                               7                No invasive or intraductal tumor        1
  Other                                 3                ER status, *n*                          
  History of other cancer, *n*                           Positive                                5
  Present                               10               Negative                                4
  Absent                                11               Not known                               1
  Local recurrence, *n*                                  PR status, *n*                          
  None                                  13               Positive                                4
  Single                                2                Negative                                5
  Multiple                              5                Not known                               1
  Persistent disease                    1                HER2/neu status, *n*                    
  Metastasis, *n*                                        Positive                                5
  Yes                                   3                Negative                                3
  No                                    18               Not known                               2
  Vital status at last follow-up, *n*                    Vital status at last follow-up, *n*     
  Dead                                  6                Dead                                    1
  Alive                                 11               Alive                                   3
  Lost to follow-up                     4                Lost to follow-up                       6
  Overall survival, %                   62               Overall survival, %                     90
  Disease-specific survival, %          81               Disease-specific survival, %            90

Abbreviations: IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; HER2, Human epidermal growth factor receptor-2.

cancers-11-00754-t002_Table 2

###### 

Clinical-pathologic findings by patient in patients with extramammary Paget disease (EMPD).

  Case                                       PD-L1 in Tumor Cells by Visual Analysis (H-Score)   Density of Marker-Positive Cells in Immune Infiltrate by Image Analysis, Positive Cells/mm^2^   PD-L1 in Immune Infiltrate by Visual Analysis (H-Score)   Anatomic Site   Associated Invasive Component   Site of Metastasis                     Survival                                                                                                                                                                                                              
  ------------------------------------------ --------------------------------------------------- ----------------------------------------------------------------------------------------------- --------------------------------------------------------- --------------- ------------------------------- -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------
  Intraepithelial disease without invasion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1                                          0                                                   1650.3                                                                                          991.4                                                     190.0           1                               Vulva                                  Absent                                                                                                                                                      NA                                                        AWOD
  2                                          15                                                  1062.1                                                                                          475.1                                                     103.6           1                               Perianal                               Absent                                                                                                                                                      NA                                                        AWOD
  3                                          0                                                   678.1                                                                                           255.0                                                     185.9           2                               Scrotum                                Absent                                                                                                                                                      NA                                                        AWOD
  4                                          0                                                   2045.8                                                                                          684.2                                                     212.0           20                              Vulva                                  Absent                                                                                                                                                      NA                                                        AWOD
  5                                          0                                                   908.1                                                                                           509.2                                                     32.4            0                               Suprapubic skin                        Absent                                                                                                                                                      NA                                                        Died of unrelated cause
  6                                          0                                                   1484.2                                                                                          1195.8                                                    177.0           1                               Perianal                               Absent                                                                                                                                                      NA                                                        AWOD
  7                                          0                                                   481.2                                                                                           294.9                                                     115.6           0                               Axilla                                 Absent                                                                                                                                                      NA                                                        Died of unknown cause
  8                                          0                                                   288.5                                                                                           121.7                                                     40.2            0                               Vulva                                  Absent                                                                                                                                                      NA                                                        Lost to follow-up
  9                                          2                                                   1039.2                                                                                          395.6                                                     277.5           2                               Perianal                               Absent                                                                                                                                                      NA                                                        AWD
  10                                         0                                                   2114.9                                                                                          1190.5                                                    167.3           60                              Scrotum                                Absent                                                                                                                                                      NA                                                        AWOD
  11                                         0                                                   492.7                                                                                           169.6                                                     57.1            2                               Scrotum                                Absent                                                                                                                                                      NA                                                        Died of unknown cause
  12                                         0                                                   261.7                                                                                           187.8                                                     82.6            1                               Perianal                               Absent                                                                                                                                                      NA                                                        Lost to follow-up
  13                                         0                                                   1970.9                                                                                          1263.0                                                    330.4           1                               Scrotum                                Absent                                                                                                                                                      NA                                                        Lost to follow-up
  14                                         0                                                   543.1                                                                                           237.8                                                     14.4            2                               Scrotum                                Absent                                                                                                                                                      NA                                                        AWD
  Invasive disease without metastasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  15                                         0                                                   598.7                                                                                           225.7                                                     33.5            1                               Perianal                               Focal dermal invasion                                                                                                                                       NA                                                        Lost to follow-up
  16                                         0                                                   No analysis                                                                                     No analysis                                               No analysis     0                               Nose tip                               Concurrent invasive adenocarcinoma in dermis of possible eccrine origin                                                                                     NA                                                        AWOD
  17                                         0                                                   1136.4                                                                                          484.8                                                     49.0            0                               Vulva, perianal, vaginal, ectocervix   Invasive poorly differentiated adenocarcinoma in urinary bladder consistent with origin from EMPD 11 years after initial diagnosis (CK7+, CK20− GCDFP15+)   NA                                                        AWOD
  18                                         0                                                   1927.3                                                                                          1207.0                                                    251.0           2                               Vulva                                  Dermal invasion present (depth \<0.5 mm)                                                                                                                    NA                                                        AWD
  *Invasive disease with metastasis*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  19                                         1                                                   No analysis                                                                                     No analysis                                               No analysis     1                               Scrotum                                Dermal and lymphovascular invasion                                                                                                                          Lymph nodes, skin, soft tissue, peritoneum, liver, bone   DOD
  20                                         0                                                   No analysis                                                                                     No analysis                                               No analysis     0                               Scrotum                                Dermal invasion and concurrent rectal adenocarcinoma (CK7+, CK20+, CDX2−)                                                                                   Lymph nodes, liver                                        DOD
  21                                         0                                                   728.5                                                                                           389.3                                                     40.5            10                              Vulva                                  Dermal invasion (depth 10 mm)                                                                                                                               Lymph nodes, liver                                        DOD

Abbreviations: NA, not applicable; AWOD, alive without disease; AWD, alive with disease; DOD, died of disease; CK, cytokeratin; GCDFP 15, Gross cystic disease fluid protein 15.
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